Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in Ordinary share ADRs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction notification and does not contain financial performance data.
Material Changes
The filing details a transaction on September 28, 2009, involving the sale of 95 Ordinary share ADRs by Mrs. S. Burns at a price of $39.70 per ADR. The company and the individual were advised of this information on December 16, 2009.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the specified transaction.
Key Facts for Investor Verification
- Transaction Date: September 28, 2009
- Transaction Type: Sale of Ordinary share ADRs
- Individual Involved: Mrs. S. Burns
- Volume: 95 ADRs
- Price per ADR: $39.70
- Notification Date to Company: December 16, 2009